Liquid Biopsy Market Analysis & Forecast: 2026-2033

Liquid Biopsy Market Size and Share Analysis – 2026 To 2033

The Liquid Biopsy Market is anticipated to grow at a CAGR of 27.5% with USD 1,354.0 Mn share in 2026 and is expected to reach USD 7,340 Mn in 2033.  The rising global cancer incidence (according to the data published by the American Cancer Society (ACS), at least 40% of new cancers diagnosed in U.S. Increasing demand for non-invasive diagnostics, and growing adoption of precision oncology drive market growth, supported by advancements in circulating tumor DNA (ctDNA) and RNA profiling technologies and expanding clinical applications in early cancer detection and treatment monitoring.

Key Takeaways

• ctNA (Circulating Tumor Nucliec Acids) is expected to account the largest share of 48.0% in 2026, driven by the rising global aging population. According to the data published by World Health Organization in February 2025, by 2030, there will be 1.4 billion people in the globe who are 60 years old or older. This is up from 1.1 billion in 2023.
• Based on Sample Type, Blood will dominate with 70.5% in 2026, as blood collection is simple, quick and widely practiced.
• On the basis of End User, hospitals hold the dominant share of 43.5% in 2026 on account of their ability to handle high patient volumes, government support, and strong adoption of advanced technologies (NGS, PCR). For instance, in March 2026, the Indian government issued milestone‑based funding (up to ₹50 lakh, scalable to ₹1 crore) for projects using AI in cancer screening and early diagnosis. The Union Budget for 2026–27 raised the Ministry of Health and Family Welfare's budget to ₹1,06,530.42 crore, which is nearly 10% more than the previous year. This means that the government would be giving more money to hospitals, diagnostic centers, research, and care facilities across the country.
• On the basis of region, North America is expected to acquire the dominant share of 46.50% in 2026, attributed to high healthcare spending, and early adoption of innovative technologies. In 2024, the U.S. spent more than 7% more on health care, reaching over 5 trillion dollars, or USD 15,474 per person.

Current Events and Their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Why is ctNA (Circulating Tumor Nucliec Acids) Acquiring the Largest Market Share?

ctNA (Circulating Tumor Nucliec Acids) is projected to account for the largest share of liquid biopsy in 2026, representing approximately 48.0% of the total volume. ctNA (Circulating Tumor Nucliec Acids) can detect tumor-specific mutations even at very low concentrations. It enables early-stage cancer detection, where other biomarkers (like CTCs) often fail.  ctNA (Circulating Tumor Nucliec Acids) is extracted directly from blood samples and there is no need for complex cell isolation (unlike circulating tumor cells) and supports frequent, repeat testing. It has wide clinical applications in cancer screening, therapy selection, prognosis and recurrence monitoring and hence, broad usage increases market adoption. Growing regulatory approvals and commercial tests supports the dominance of the segment in the market. For instance, in January 2026, the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic for the Pfizer colorectal cancer treatment (BRAFTOVI + cetuximab) in those with BRAF V600E-mutant metastatic colorectal cancer. This was a big step forward for the use of ctDNA liquid biopsy in clinical practice. It allows for quick genomic profiling from a simple blood sample to find actionable mutations that help doctors decide on targeted therapy, especially when traditional tissue biopsies are hard to get or don't give enough information. The clearance also made it useful for more types of cancer than just lung and breast cancer. It was also covered by major payer plans, making it easier for doctors and patients to get.

Furthermore, precision oncology is increasing demand for rapid detection of actionable mutations to guide targeted therapy due to which the demand for the ctDNA has increased. For instance, in September 2025, according to the study carried out by the European Society of Medicine, recent clinical studies indicate that next-generation sequencing (NGS)–based liquid biopsies consistently identify actionable mutations in ctDNA among patients with advanced non-small cell lung cancer (NSCLC), even in the absence of tumor tissue samples for analysis. In a real-world observational study published in 2025–2026, ctDNA analysis detected actionable mutations in 41.6% of NSCLC patients with restricted tissue availability, including common driver changes such as EGFR, ALK, KRAS G12C, RET, and ERBB2 variations. These results allowed doctors to start matched targeted medicines (such EGFR tyrosine kinase inhibitors and ALK inhibitors) faster than they could have with tissue testing alone. This sped up the process of making precise treatment decisions in a real clinical setting.

Blood holds the Largest Market Share

To learn more about this report, Download Free Sample

Based on sample type, blood dominate the market, accounting for a significant 70.5% share in 2026, owing to minimally invasive nature, high biomarker availability, and compatibility with advanced technologies. Rising cancer burden due to aging population globally has increased demand for early and non-invasive diagnostics, which has estimated to drive the growth of the segment in the near future. For instance, in 2026, according to the data published by the National Center for Biotechnology Information, it has been estimated that due to an aging population and lifestyle factors, the number of new cases of cancer in India is expected to increase from roughly 1.4–1.5 million in 2022–2024 to 1.57–1.87 million by 2026. Cancer cases in India may increase by 67% by 2045. This means that early detection is crucial for a disease that has the third-highest incidence in the world. By 2045, incidence is predicted to grow to over 2.45 million.

Which End User segment dominates the market?

Hospitals account for the largest share of 43.5% in 2026 due to their advanced infrastructure, access to skilled physicians, and ability to handle high patient volumes. Hospitals are the first contact for cancer diagnosis and treatment which handle large patient volumes, leading to higher test utilization. Hospitals have integrated oncology infrastructure which means availability of pathology labs, oncology departments, and imaging facilities which enables end-to-end cancer managements in one place. Many hospitals have advanced molecular diagnostic labs which can perform liquid biopsy tests internally with faster turnaround time. Rising government & private investments and funding for diagnostic laboratories and cancer care centers rises the liquid biopsy market demand in hospitals.  For instance, in January 2026, MedPark Hospital, unveiled Genomics Laboratory in January 2026 and stated that its NGS capabilities lets them analyze numerous genes with high resolution and a faster turnaround time to help with diagnosis, risk assessment, and treatment planning. In January 2026, 4baseCare announced the first close of a Rs 90 crore Series B round in India. In March 2026, it announced a partnership with the Government of Maharashtra to set up a Centre of Excellence for Precision Oncology that will use NGS technology and the AI-powered OncoTwin platform to make treatment decisions that are more personalized and based on data. In addition, in 2026, investments like UMMC's USD 125 million cancer center campaign, UC Davis' US$2 million early-detection grant, Illumina-Labcorp's expanded precision-oncology testing collaboration, MedPark's genomics lab launch, and 4baseCare's Rs 90 crore funding and Maharashtra precision-oncology center partnership showed how money is making the ecosystem better for finding advanced cancer and choosing the right treatment.

Liquid Biopsy Market Drivers

Rising Geriatric Population

Increasing aging population has significantly driven the growth of the market. Aging population higher cancer risk and increases demand for diagnostics. For instance, in October 2025, according to the data published by the World Health Organization, it has been estimated that by 2050, 80% of elderly people will live in nations with low or middle incomes. One out of every six persons in the globe will be 60 years old or older by 2030. The number of people aged 60 and over will rise from 1 billion in 2020 to 1.4 billion at this time. By the year 2050, there will be 2.1 billion people in the globe who are 60 years old or older. By 2050, the number of people who are 80 years old or older is predicted to treble, reaching 426 million.

(Source: WHO)

Increasing Awareness & Screening Programs

Government campaigns, media, and healthcare initiatives educate people about cancer risks and importance of early diagnosis. More people become proactive about health check-ups. Awareness leads to more people enrolling in cancer screening camps which increases screening volume significantly.  People prefer less painful and convenient tests and liquid biopsy (blood-based) becomes a preferred option over tissue biopsy. In February 2026, World Cancer Day (February 4, 2026) is still a big event that raises awareness around the world. Its topic is early identification and screening for cancer. Public health advertising, educational messages, and outreach are all part of this occasion. They all stress how important screening methods like blood testing and cancer marker tests are for finding cancer earlier in people who don't have any symptoms.

Furthermore, in February 2026, the U.S. passed the Medicare Multi-Cancer Early Detection Coverage Act, which set up a means for Medicare to pay for FDA-approved multi-cancer early detection (MCED) tests, most of which are based on liquid biopsies. This strategy helps make advanced blood-based cancer screening a regular part of healthcare for older persons. This helps with early diagnosis and makes sure that both doctors and patients know about it. Coverage support also helps people use a product and get paid for it, which can speed up adoption.

Moreover, in May 2025, NHS England became the first healthcare system to routinely use a liquid-biopsy blood test for suspected lung cancer before a tissue biopsy in about 176 hospitals. This led to the use of liquid biopsy in real-world screening and diagnostic workflows, speeding up focused therapy and cutting down on unneeded invasive procedures.

Role of R&D and Innovation in Transforming the Liquid Biopsy Landscape

Increasing research & development and product innovation has created significant opportunity for the growth of the market in the near future. Development of new assays and multi-cancer early detection (MCED) tests drives future growth. For instance, in January 2026, GRAIL, Inc., a healthcare company whose goal is to find cancer early when it can be treated, sent the last part of its Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) test to the U.S. Food and Drug Administration (FDA). Furthermore, in January 2026, Caris Life Sciences, a top AI TechBio company that focuses on patients and is a leader in precision medicine, has teamed up with Everlywell, a digital health company that is leading the way in the next generation of biomarker intelligence by combining AI-powered technology with human insight to give people personalized, actionable health answers. Caris Life Sciences, biotech company and Everlywell entered into partnership to produce Caris Detect, a blood-based screening test for several cancers that will be available on Everlywell's platform. Caris Detect uses whole genome sequencing (WGS) technology to look for different types of cancer by looking at molecular signals that are in the blood.

(Source: Caris Life Sciences)

Liquid Biopsy Market Trends

• The adoption of liquid biopsy technologies to monitor genomic changes in real-time contributes to the growth of the market, especially in targeted therapies.
• Rising demand for non-invasive diagnostics has significantly driven the growth of the market. The market is still growing because more and more people want non-invasive procedures, such as liquid biopsy tests that can find cancer early. Liquid biopsy is a less intrusive way to do a biopsy than a typical tissue biopsy. It can find circulating tumor DNA (ctDNA), RNA, and tumor cells in blood samples.
• Efforts to broaden clinical access to liquid biopsy testing is the major trend driving the liquid biopsy market growth over the forecast period. For instance, in March 2026, Illumina, Inc., biotechnology company expanded collaboration with Labcorp, biopharma company, to improve precision oncology by using next-generation sequencing (NGS) solutions in new ways throughout the healthcare system. Projects should include making cancer biomarker testing more fair by making it easier for patients to get to by offering new dispersed tests; gathering evidence to make it easier for payers to cover the tests; and creating additional tests to fill in gaps in care.
• Rapid shift towards precision medicine has increased the demand for the biopsy as liquid biopsy is becoming central to personalized cancer treatment it helps in mutation detection and targeted therapy selection. Precisoion diagnostics are core to oncology care.
• Growing use of liquid biopsy in minimal residual disease (MRD) monitoring is one the factor fueling the liquid biopsy market demand. Increasing adoption for detecting residual cancer after treatment and early relapse detection is emerging as a high-growth clinical application.

Regional Insights

To learn more about this report, Download Free Sample

Technological Innovations & Government Support in North America is driving the dominance

North America is expected to account for a dominant 46.50% market share, supported by early adoption innovative technologies, advanced healthcare infrastructure, and strong presence of key market players. Headquarters of major companies like Guardant Health, ILLumina, and Bio-Rad are in North America region which leads to higher product availability and commercialization. Significant spending on cancer care and advanced diagnostics enables affordability and accessibility in the region.

North America is home to a robust healthcare ecosystem, with significant investments in cancer care centers and diagnostic technologies. For instance, in April 2026, the American Cancer Society, revealed announced an USD 80.7 million investment in new cancer research grants across 128 projects at 71 U.S. institutions, aimed at advancing cancer detection, treatment, and survivorship research a major funding boost for innovative work spanning early diagnostics to precision therapies. The American Cancer Society states that the new slate covers a wide spectrum of studies in areas like cancer prevention, detection, treatment, survivorship, and more throughout the cancer control continuum. In 2026, federal funding for the National Cancer Institute (NCI) went raised to about USD 7.35 billion. This included research project awards that help pay for the infrastructure for clinical and translational cancer research at major cancer centers across the country. Furthermore, in the private sector, Precede Biosciences, a Boston-based biotechnology company raised roughly US$84 million in January 2026 to improve its liquid biopsy platform, which is meant to work with next-generation precision cancer treatments. This shows that investors have a lot of faith in new commercial diagnostic technologies.

Asia Pacific Liquid Biopsy Market Trends

The Asia-Pacific region is poised to be as the fastest-growing region through 2026-2033, owing to improving healthcare infrastructure, growing awareness of early diagnosis and large patient population. Asia Pacific has a huge population base which leads to high testing volumes and market potential. Rising adoption of advanced technologies for diagnosis purpose accelerates liquid biopsy market growth. Many Asia‑Pacific countries have aging populations, where cancer risk increases, further driving demand for effective diagnostic solutions. For instance, according to the data published by the UNFPA (United Nations Population Fund) it has been estimated that by 2050, the number of persons in Asia-Pacific who are 60 years old or older is predicted to rise from 2010 to 1.3 billion. This shows that the population is quickly getting older. By 2050, over one in four people in the area will be over 60 years old. This shows how quickly the population is getting older. Another estimate says that by 2029, the area might have more than 548 million people aged 65 and more, which would be a big part of the world's senior population development. Parts of the Asia-Pacific region, like Singapore, are anticipated to become "super-aged" societies by 2030, with more than 20% of the population being 65 or older. Data modeling shows that the percentage of individuals in Asia who are 65 or older could go up a lot, to 18% by 2050.

Rising Cancer Prevalence is accelerating the Liquid Biopsy Market Demand in United States

The U.S. liquid biopsy market is undergoing a period of robust expansion. The growth is fueled by a rapidly rising cancer prevalence, for instance, in 2026, according to the data published by the American Cancer Society, it has been estimated that in 2026, the United States is expected to have about 2,114,850 new cancer cases and 626,140 cancer deaths. Furthermore, support from the U.S. Food and Drug Administration (U.S. FDA) drives the liquid biopsy market growth in the U.S. country. For instance, in August 2025, the U.S. Food and Drug Administration (FDA) has given Breakthrough Device Designation to Quest Diagnostics' Haystack MRD test, which is used to find MRD-positive patients with stage II colorectal cancer who have had curative-intent surgery and may benefit from adjuvant therapy. The new designation adds to the growing body of evidence that the Haystack MRD test is useful for both medical and drug development purposes. It also fits with a lot of research that shows ctDNA-based MRD testing could find leftover or recurring malignancy from solid tumors.

China Liquid Biopsy Market Trends

The China liquid biopsy projected to grow significantly during the upcoming years. China accounts for a major share of Asia Pacific healthcare spending which leads to higher adoption of advanced diagnostics. National programs for cancer prevention and early detection accelerates liquid biopsy market growth and adoption. Moreover, presence of domestic market players in China drives the liquid biopsy market size in Asia Pacific region. Growing number of Chinese biotech and diagnostic companies enhances local production and affordability. For instance, Burning Rock Biotech Ltd, biotech company based in Guangzhou, China is still one of the top companies in China for liquid biopsy technology. In early 2026, the company received Breakthrough Device Designation from China's NMPA for its multi-cancer early detection blood test. This shows that there are more interest and regulatory support for domestic liquid biopsy solutions. Furthermore, in December 2025, Pillar Biosciences, biotechnology company, unveiled that it would be adding China to its existing laboratory access arrangement with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling.  The goal of this expanded partnership is to provide quick, cheap, and therapeutically useful genetic information through liquid biopsy testing. The partnership's goal is to speed up the time it takes to get a diagnosis and make precision oncology solutions more widely available by making plasma-based tumor profiling more widely available at top clinical labs in China. The Pillar Biosciences-AstraZeneca expansion in China, which was announced in late 2025 and will continue into 2026, is a prime instance of a recent cooperation that aims to bring advanced liquid biopsy testing to China. This shows that international and local companies are working together to improve China's diagnostic industry.

Who are the Major Companies in Liquid Biopsy Market

Some of the major key players Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.

Key News

• In March 2026, VolitionRx Limited, epigenetics company, is the first to show how to isolate and analyse circulating tumor-derived DNA (ctDNA) that is more than 99% pure. VolitionRx Limited unevield that it has sent in a latest updated manuscript called "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy”.
• In December 2025, Guardant Health, Inc., biotechnology company headquartered in California, U.S., unveiled FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This alliance is the most recent in a series of public-private partnerships that Guardant Health has made with top European academic and research hospitals. These partnerships combine Guardant Health's cutting-edge technology with existing care pathways to make it easier for more cancer patients to get the care they need. Guardant360 CDx technology will be used for on-site liquid biopsy testing at Policlinico Gemelli. The partnership makes precision oncology diagnostics more widely available and helps with both ordinary treatment and clinical research.

Market Report Scope

Liquid Biopsy Market Report Coverage

Analyst Opinion

• The global liquid biopsy market is seeing rapid growth, fueled by a rising need for less invasive cancer diagnostics. Liquid biopsy presents compelling benefits. It enables early detection, allows for real-time monitoring, and can analyze multiple biomarkers from a single blood sample. This push for better diagnostic tools is propelling market expansion, especially within oncology. Early-stage detection and monitoring minimal residual disease (MRD) are crucial in this field. Liquid biopsy has become a key player in oncology diagnostics, particularly for non-small cell lung cancer (NSCLC). Studies indicate that more than 90% of NSCLC patients gain from ctDNA-based testing, which aids in selecting targeted therapies and tracking treatment effectiveness. This non-invasive approach is driving growth in the market, as clinical data increasingly supports its effectiveness in early-stage detection and disease progression monitoring.
• The rising incidence of cancer worldwide further supports the adoption of liquid biopsy technologies. According to the WHO, cancer cases are projected to increase significantly in the coming decades, with over 23 million new cases expected by 2030. As the prevalence of cancer rises, liquid biopsy provides an essential tool for detecting cancer early, enabling better treatment outcomes.
• Liquid biopsy is becoming more popular because of advances in technology. Some important changes are better ways to profile circulating tumor DNA (ctDNA) and RNA, which make liquid biopsy testing more accurate and dependable. The combination of AI and machine learning technology is also making it easier to understand complicated genomic data, which is speeding up the use of liquid biopsy in both clinical and research contexts. For instance, in March 2026, VolitionRx Limited announced a significant technological advancement in liquid biopsy by attaining over 99% purity in the isolation of circulating tumor-derived DNA (ctDNA) for analysis. The company was able to physically enrich cancer-derived DNA and remove practically all normal background cell-free DNA from samples using its new Capture-Seq technology. This led to almost pure ctDNA sequencing data sets.

Market Segmentation

• By Biomarker Type
  • CTC (Circulating Tumor Cells)
  • ctNA (Circulating Tumor Nucliec Acids)
  • Exosomes
• By Device Type
  • Blood
  • Urine
  • Others
• By Disease Indication
  • Lung Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Others
• By End User
  • Hospitals
  • Cancer Institutes
  • Academic Institutes
  • Diagnostic Centers
• Global Liquid Biopsy Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Biocept, Inc.
  • Qiagen N.V.
  • Trovagene, Inc.
  • Janssen Global Services
  • LLC, MDxHealth SA, Natera, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Silicon Biosystems
  • Pathway Genomics Corporation
  • Sysmex Corporation

Sources

Primary Research Interviews

• Interviews with oncologists, pathologists, and clinical trial coordinators across key regions (North America, Europe, and Asia-Pacific)
• Insights from biotech and pharmaceutical companies, diagnostic laboratories, and healthcare providers involved in liquid biopsy development and testing
• Discussions with regulatory experts, reimbursement advisors, and healthcare professionals on product approval, adoption challenges, and patient preferences for liquid biopsy in cancer diagnostics

Databases

• PubMed Central – A repository for academic research papers, including those on diagnostic tests and the development of liquid biopsy.
• ClinicalTrials.gov – Includes a wide range of clinical trials on liquid biopsy tests for cancer diagnosis and monitoring.
• European Bioinformatics Institute (EBI) – Provides data related to biomarkers used in liquid biopsy for cancer diagnosis.
• National Cancer Institute (NCI) – Provides comprehensive data on cancer diagnostics, including liquid biopsy techniques for early detection.
• American Cancer Society (ACS) – Offers detailed reports and studies on cancer, diagnostic technologies, and advancements in liquid biopsy.

Magazines

• Genetic Engineering & Biotechnology News (GEN)
• Nature Biotechnology
• Cancer Science & Therapy
• The Cancer Letter

Journals

• Clinical Cancer Research
• Cancer Research
• Annals of Oncology
• The Journal of Clinical Oncology
• Nature Reviews Cancer

Newspapers

• The Guardian (Health Section)
• The Wall Street Journal (Health Section)
• The New York Times (Health Section)

Associations

• American Association for Cancer Research (AACR)
• European Society for Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• International Association for the Study of Lung Cancer (IASLC)
• National Comprehensive Cancer Network (NCCN)

Public Domain Sources

• Company Annual Reports and Investor Presentations
• World Health Organization (WHO) Publications on Cancer
• Government Health Ministry Publications (e.g., U.S. FDA, EMA)
• Clinical Trial Registries such as ClinicalTrials.gov

Proprietary Elements

• CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years